Search the Newsreel

Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash

Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …

Form 8K Arcadia Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Arcadia Biosciences Inc. on August 13. The company's stock symbol is RKDA, and its shares experienced a 9.60% increase. The brief announcement provides no further details about the content of the 8K filing.

Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings, beating analyst expectations with an adjusted loss of $0.20 per share, $0.52 better than forecast, and revenue of $13.37 million, exceeding estimates of $8.60 million. Following the news, shares rose significantly by $2.89 to $29.95 on high trading …

Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake

Yuling Luo has disclosed a 6.4% beneficial ownership stake in Alamar Biosciences (ALMR) through a Schedule 13G filing. This amounts to 4,528,718 shares, including those with sole and shared voting/dispositive power, and shares exercisable via stock options within 60 days. The ownership percentage is …

Transcript : Microbix Biosystems Inc., Q3 2026 Earnings Call, Aug 13, 2026

Ensysce Q2 Results: EPS beats estimate, sales up 16% vs view

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) reported a Q2 loss of $0.24 per share, outperforming the Zacks Consensus Estimate of a $0.33 loss. However, the company missed revenue estimates, posting $1.5 million against an expected $2.5 million. The stock currently holds a Zacks Rank #3 (Hold), …

Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Arcadia Biosciences: Q2 Earnings Snapshot

Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences announced its Q2 2026 financial results, highlighted by the acquisition of Cy Biopharma, Inc., which adds CY200 for Complex Regional Pain Syndrome (CRPS) to its pipeline. This acquisition, coupled with private placement financings, provides up to $77 million in new funding, extending …

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences has released its financial results for the second quarter of 2026, alongside a business update. The report details the company's financial performance and highlights recent developments in its operations and strategic initiatives.

Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss

Caribou Biosciences reported its Q2 2026 financial results, showing $1.5 million in licensing revenue and a GAAP net loss of $24.3 million. The company holds $113.8 million in cash and expects these funds to support operations through the end of 2027. Business highlights include …

Caribou Biosciences Q2 Results: Net loss narrows to $24.3 million

Caribou Biosciences reported a narrowed net loss of $24.3 million in Q2 2026, significantly improving from $54.1 million in Q2 2025, beating EPS estimates. This was primarily due to a sharp decline in operating expenses and cost-cutting measures. However, quarterly sales missed analyst forecasts, …

Caribou Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Caribou Biosciences, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement from Reuters, indicating that a full report is available to subscribers of TradingView.

Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake

Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …

Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Assembly Biosciences: Q2 Earnings Snapshot

Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G

A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power …

Artisan Partners group (TWST) discloses 4.8M-share position in Twist Bioscience

Artisan Partners Asset Management Inc. and its affiliates have disclosed a beneficial ownership of 4,802,017 common shares, representing a 7.7% stake, in Twist Bioscience Corporation (TWST). This position is held on behalf of Artisan Partners Limited Partnership's discretionary clients, with shared voting power over …

Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due

Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …

CuriosityStream (NASDAQ: CURI) posts higher Q2 2026 profit on licensing surge

Daré Bioscience launches Flora Sync, its first directly commercialized product

Daré Bioscience (NASDAQ: DARE) reported Q2 2026 revenue of $0.19 million, a net loss of $3.0 million, and $12.6 million in cash and equivalents. The company announced the launch of Flora Sync LF5, its first directly commercialized product, which began generating revenue in July …

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Daré Bioscience reported its Q2 2026 financial results, highlighting significant progress in its multi-product women's health strategy. The company launched Flora Sync LF5 and is preparing for national dispensing of DARE to PLAY Sildenafil Cream, expecting initial revenue in Q3 2026. Daré also provided …

Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary

Dare Bioscience, Inc. reported its 2026 quarterly results, with revenue of $187.55K and a net loss of ($2.98M), which is an improvement from the prior year's loss. The company saw revenue growth due to Gates Foundation agreements and the launch of new products and …

Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data

Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …

Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients

Caribou Biosciences reported its Q2 2026 financial results and provided an update on its CAR-T pipeline. The company's vispa-cel therapy for large B cell lymphoma showed an 82% overall response rate, while CB-011 for multiple myeloma achieved a 92% overall response rate in a …

VRTS Looks 10.5% Undervalued on GF Value™ Despite Cash-Flow Chal

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences (NASDAQ: CSTL) raised its full-year outlook after exceeding second-quarter expectations, primarily driven by strong performance from its DecisionDx-Melanoma and TissueCypher tests, along with increased physician adoption. The DecisionDx-Melanoma test continues to be a key growth driver, showing mid- to high-single-digit volume growth, …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?

Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% …

Why Did CuriosityStream Stock Rocket Higher Today?

CuriosityStream (NASDAQ: CURI) stock rocketed over 50% after releasing its second-quarter earnings last night. There were good reasons for the massive move, too. Shares of the company aren't soaring because of its on-demand streaming service. Rather, it is due to the company's move to …